Back

Obesity Medicine Association

  • Glucagon-Like Peptide-1 Receptor Agonists
  • Obesity
  • Problem Solving

Obesity Medicine 2025 – Muscle Safety: Addressing GLP-1 Agonist Concerns with Exercise & Nutrition (Recorded)

The rise in the use of glucagon-like peptide 1 receptor agonists (GLP-1RA) for weight loss has generated significant interest due to their efficacy in reducing body weight. However, this trend has also highlighted a critical health concern: the unintended loss of muscle mass. While these therapies effectively shed excess pounds, they also contribute to a decrease in muscle mass, raising concerns about the potential long-term impact on overall health. This is of particular concern for individuals already at risk for age-related impairments in muscle mass and function, such as middle-aged and older adults. This session is important for filling current practice and knowledge gaps, providing clinicians with strategies to optimize patient outcomes in the context of GLP-1RA therapy. It is structured to be both informative and interactive, incorporating visuals, thought-provoking questions, and problem-solving exercises and to equip attendees with the tools and knowledge necessary to optimize GLP-1RA therapies in their daily clinical practice, ultimately leading to better patient outcomes. CME/CE Expiration Date: 4/27/28 *The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 1 credit

MOC types

ABS — Accredited CMEUp to 1 point

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

$25

Standard

Listed by the provider · academy.obesitymedicine.org

  • On-demand / recorded video
  • Credit · Up to 1 credit
  • MOC · Up to 1 point
  • $25
  • Released
    Apr 27, 2025
  • Last day to claim credit
    Apr 28, 2028 2 years left